Abstract
Adjunctive treatment in the setting of cardiovascular thrombolysis is the cornerstone to avoid recurrence establishing a bridge to starting oral anticoagulation with oral vitamin-K antagonists or activated factors anticoagulants. In addition, bleeding complications in the first 20- or 48-h could be related with the adjunctive treatment. So, it is important that physicians linked with PE patients care choose the best option. In this chapter the position of European and North American societies will be analyzed. Also, experiences with fondaparinux and unfractionated heparin regimen use in ST-myocardial infarction patients will be analyzed. Additionally, based on our previous successful experience with ST-elevation myocardial infarction regimen with a first generation fibrinolytic, we decided to use recombinant human tissue-type plasminogen activator in PE patients with efficacy and safety, as has been used in myocardial infarction patients. Although we did not have head-to head studies, less residual thrombosis with recombinant human tissue-type plasminogen activator compared with a first generation fibrinolytic was observed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galie N, Gibbs JSR, Huisman MV, Humbert M, Kucher N, Lang I, Lankeit M, Lekakis J, Maack C, Mayer E, Meneveau N, Perrier A, Pruszczyk P, Rasmussen LH, Schindler TH, Svitil P, Noordegraaf AV, Zamorano JL, Zompatori M. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:3033–80. doi:10.1093/eurheartj/ehu283.
Jaff MR, McMurtry MS, Archer SL, Cushman M, Goldenberg NA, Goldhaber SZ, Jenkins JS, Kline JA, Michaels AD, Thistlethwaite P, Vedantham S, White RJ, Zierler BK, on behalf of the American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Peripheral Vascular Disease, and Council on Arteriosclerosis, Thrombosis and Vascular Biology. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation. 2011;123:1788–830. doi:10.1161/CIR.0b013e318214914f.
Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e419S–94.
Janin S, Meneveau N, Mahemuti A, Descotes-Genon V, Dutheil J, Chopard R, Seronde MF, Schiele F, Bernard Y, Bassand JP. Safety and efficacy of fondaparinux as an adjunctive treatment to thrombolysis in patients with high and intermediate risk pulmonary embolism. J Thromb Thrombolysis. 2009;28:320–24.
Buller HR, Davidson BL, Decousus H. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med. 2004;140:867–73.
Buller HR, Davidson BL, Decousus H. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003;349:1695–702.
Turpie AG, Bauer KA, Eriksson BI. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med. 2002;162:1833–40.
Yusuf S, Mehta SR, Chrolavicius S. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006;295:1519–30.
Meneveau N, Seronde MF, Blonde MC. Management of unsuccessful thrombolysis in acute massive pulmonary embolism. Chest. 2006;129:1043–50.
Jerjes-Sanchez C, Villarreal-Umaña S, Ramirez-Rivera A, Garcia-Sosa A, Canseco LM, Archondo T, Reyes E, Garza A, Arriaga R, Castillo F, Jasso O, Garcia H, Bermudez M, Hernández JM, Garcia J, Martinez P, Rangel F, Gutierrez J, Comparan A. Improving adjunctive treatment in pulmonary embolism and fibrinolytic therapy. The role of enoxaparin and weight-adjusted unfractionated heparin. J Thromb Thrombolysis. 2009;27:154–62.
The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abxicimab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet. 2001;358:605–13.
Gulba DC, Tanswell P, Dechend R, Sosada M, Weis A, Waigand J, Uhlich F, Hauck S, Jost S, Raffenbeul W, Lichtlen PR, Dietz R. Sixty-minute alteplase protocol: a new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarction. J Am Coll Cardiol. 1997;30:1611–17.
Martinez SC, Dominguez JL, Aguirre SJ, Carrillo J, Chuquiure VE, Franco J. Tratamiento del infarto agudo al miocardio con rt-PA en 60 minutos. Estudio Cooperativo. Arch Inst Cardiol Mex. 1997;67:126–31.
Jerjes-Sanchez C, Ramirez-Rivera A, Garcia ML, Arriaga-Nava R, Valencia-Sanchez S, Rosado-Buzzo A, Pierzo JA, Rosas ME. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial. J Thromb Thrombolysis. 1995;2:67–9.
Jerjes-Sanchez C, Ramirez-Rivera A, Arriaga-Nava R, Iglesias-Gonzalez S, Gutierrez P, Ibarra-Perez C, Martinez A, Valencia S, Rosado-Buzzo A, Pierzo JA, Rosas E. High dose and short-term streptokinase infusion in patients with pulmonary embolism. Prospective with seven-year follow-up trial. J Thromb Thrombolysis. 2001;12:237–47.
Jerjes-Sanchez C, Elizalde GJ, Sandoval JZ, et al. Diagnostico, estratificacion y tratamiento de la tromboembolia pulmonar aguda. Guias y recomendaciones del capitulo de Circulacion Pulmonar de la Sociedad Mexicana de Cardiologia. Arch Cardiol Mex. 2004;74 Suppl 3:S547–85.
Foussas SG, Zairis MN, Lyras AG. Early prognostic usefulness of C-reactive protein added to the thrombolysis in myocardial infarction risk score in acute coronary syndromes. Am J Cardiol. 2005;96:533–37.
Becattini C, Agnelli G, Salvi A, Grifoni S, Pancladi LG, Enea I, Blasemin F, Campanini M, Ghirarduzzi A, Casazza F, TIPES Study Group. Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. Thromb Res. 2010;125:e82–6.
Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J, Bluhmki E, Bouvaist H, Brenner B, Couturaud F, Dellas C, Empen K, Granca A, Galiè N, Geibel A, Goldhaber SZ, Jimenez D, Kozak M, Kupatt C, Kucher N, Lang IM, Lankeit M, Meneveau N, Pacouret G, Palazzini M, Petris A, Pruszczyk P, Rugolotto M, Salvi A, Schellong S, Sebbane M, Sobkowicz B, Stefanovic BS, Thiele H, Torbicki A, Verschuren F, Konstantinides SV, PEITHO Investigators. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014;370:1402–11.
Kline JA, Nordenholz KE, Courtney DM, Kabrhel C, Jones AE, Rondina MT, Diercks DB, Klinger JR, Hernandez J. Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double-blind, placebo-controlled randomized trial. J Thromb Haemost. 2014;12:459–68.
Marti C, John G, Konstantinides S, Combescure C, Sanchez O, Lankeit M, Meyer G, Perrier A. Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis. Eur Heart J. 2014;36(10):605–14. doi:10.1093/eurheartj/ehu218.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Jerjes-Sánchez, C., Garcia-Sosa, A. (2015). Anticoagulation as Adjunctive Treatment and One-Hour Alteplase Infusion. In: Thrombolysis in Pulmonary Embolism. Springer, Cham. https://doi.org/10.1007/978-3-319-19707-4_5
Download citation
DOI: https://doi.org/10.1007/978-3-319-19707-4_5
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-19706-7
Online ISBN: 978-3-319-19707-4
eBook Packages: MedicineMedicine (R0)